Anti-CD20 Antibody (Rituximab Biosimilar)
Human
CD20
Human IgG1-Kappa
Unconjugated
protein A
0.2 μM filtered
PBS, 10% glycerol (pH 7.4)
Less than 1 EU per μg by the LAL method.
（Recommended Dilution Buffer）
PBS (pH 7.4), contains no stabilizers or preservatives.
<p style="line-height: 25px;">> 95% as determined by Bis-Tris PAGE<br />> 95% as determined by HPLC</p>
<p style="line-height: 25px;">Valid for 12 months from date of receipt when stored at -80°C.<br />Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.</p>
ELISA/SPR/BLI
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
(1)Ma D , Mcdevitt M R , Barendswaard E , et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies[J]. Leukemia, 2002, 16(1):60-66. (2)Jager U , Fridrik M , Zeitlinger M , et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response[J]. Haematologica, 2012, 97(9):1431-1438.
